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Effect of tranexamic acid in traumatic brain injury: a
nested randomised, placebo controlled trial (CRASH-2
Intracranial Bleeding Study)
Abstract
Objective To assess the effect of tranexamic acid (which reduces
bleeding in surgical patients and reduces mortality due to bleeding in
trauma patients) on intracranial haemorrhage in patients with traumatic
brain injury.
Methods A nested, randomised, placebo controlled trial. All investigators
were masked to treatment allocation. All analyses were by intention to
treat.
Patients 270 adult trauma patients with, or at risk of, significant
extracranial bleeding within 8 hours of injury, who also had traumatic
brain injury.
Interventions Patients randomly allocated to tranexamic acid (loading
dose 1 g over 10 minutes, then infusion of 1 g over 8 hours) or matching
placebo.
Main outcome measures Intracranial haemorrhage growth (measured
by computed tomography) between hospital admission and then 24–48
hours later, with adjustment for Glasgow coma score, age, time from
injury to the scans, and initial haemorrhage volume.
Results Of the 133 patients allocated to tranexamic acid and 137
allocated to placebo, 123 (92%) and 126 (92%) respectively provided
information on the primary outcome. All patients provided information
on clinical outcomes. The mean total haemorrhage growth was 5.9 ml
(SD 26.8) and 8.1 mL (SD 29.2) in the tranexamic acid and placebo
groups respectively (adjusted difference –3.8 mL (95% confidence
interval −11.5 to 3.9)). New focal cerebral ischaemic lesions occurred
in 6 (5%) patients in the tranexamic acid group versus 12 (9%) in the
placebo group (adjusted odds ratio 0.51 (95% confidence interval 0.18
to 1.44)). There were 14 (11%) deaths in the tranexamic acid group and
24 (18%) in the placebo group (adjusted odds ratio 0.47 (0.21 to 1.04)).
Conclusions This trial shows that neither moderate benefits nor
moderate harmful effects of tranexamic acid in patients with traumatic
brain injury can be excluded. However, the analysis provides grounds
for further clinical trials evaluating the effect of tranexamic acid in this
population.
Trial registration ISRCTN86750102.
Introduction
The antifibrinolytic tranexamic acid has been shown to reduce
blood loss in surgical patients and the risk of death in patients
with traumatic bleeding, with no apparent increase in vascular
occlusive events.1 2 These findings raise the possibility that it
might be effective in other situations in which bleeding can be
life threatening or disabling.
Traumatic brain injury is a leading cause of death and disability
worldwide. Each year more than 1.5 million people die and
about 10 million people are hospitalised after traumatic brain
injury.3 A complication of such injury is intracranial
haemorrhage. Its frequency varies according to the injury
severity. In the MRC CRASH Trial, which included patients
with mild, moderate, and severe traumatic brain injury, three
quarters of patients had intracranial haemorrhage.4 In about half
of patients with intracranial haemorrhage the lesion enlarges
after hospital admission.5 6 Patients with large haemorrhages
are at substantially greater risk of death than those with small
haemorrhages.7
About a third of patients with traumatic brain injury have
coagulopathy. Those with coagulopathy have an increased risk
of haemorrhage growth and higher mortality.8 Increased
fibrinolysis, as indicated by high levels of fibrinogen degradation
products, is a common feature of the coagulopathy in traumatic
brain injury, raising the possibility that tranexamic acid might
reduce traumatic intracranial haemorrhage.9 To date, there have
been no randomised controlled trials of tranexamic acid in
traumatic brain injury.10
The CRASH-2 trial recruited 20 211 trauma patients with, or
at risk of, significant (extracranial) haemorrhage. Although
traumatic brain injury was not an inclusion criterion, it is likely
that a substantial proportion of included patients would also
have had traumatic brain injury. However, to keep data
collection to a minimum, and ensure recruitment to detect the
main outcome (overall mortality), computed tomography data
were not routinely collected. Nevertheless, the CRASH-2 trial
represented a unique opportunity to nest an exploratory study
collecting computed tomography data to evaluate the effect of
tranexamic acid on outcomes in patients with traumatic brain
injury. The CRASH-2 Intracranial Bleeding Study was a
prospective randomised controlled trial nested within the
CRASH-2 trial to quantify the effect of an early short course of
tranexamic acid on intracranial haemorrhage in patients with
traumatic brain injury.
Computed tomogram rating forms used in study (see http://www.bmj.com/content/343/bmj.d3795/suppl/DC1)
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Methods
Trial design—This double blind, randomised, placebo controlled
trial was nested in a cohort of CRASH-2 trial participants. The
aims, methods, and results of the CRASH-2 trial are presented
in detail elsewhere.2
Participants—The trial was conducted in a cohort of CRASH-2
trial participants. Patients eligible for inclusion in the Intracranial
Bleeding Study fulfilled the inclusion criteria for the CRASH-2
trial—adult trauma patients with significant haemorrhage
(systolic blood pressure <90 mm Hg or heart rate >110 beats
per min, or both) or who were considered to be at risk of
significant haemorrhage, and whowere within 8 hours of injury
(study entry governed by the uncertainty principle)11—but they
also had traumatic brain injury (Glasgow coma scale ≤14 and
a brain computed tomography compatible with traumatic brain
injury). Pregnant women and patients for whom a second brain
scan was not possible were excluded. Consent procedures at
participating hospitals were established by local regulation and
the appropriate ethics committees.
Study settings—Patients were recruited from 10 hospitals in
India and Colombia. The sites were selected according to their
interest in the topic, adequate facilities for conducting computed
tomography, and expected recruitment rate.
Interventions
Participants were randomly allocated to receive a loading dose
of 1 g tranexamic acid infused over 10 minutes, followed by an
intravenous infusion of 1 g over eight hours, or matching
placebo (sodium chloride 0.9%).
Outcomes
We obtained two brain computed tomograms for each
participant, the first before randomisation and the second 24–48
hours later. A neuroradiologist (Zoe Morris) who was blind to
treatment allocation and clinical findings evaluated the first and
second scans. Readings of the two scans were done twice (with
the second reading blind to the results of the first reading) by
central reading of the electronic DICOM image files in Digital
Jacket software (DesAcc, Chicago IL, USA). The size of
intra-parenchymal haemorrhages, haemorrhagic contusions,
subdural epidural haematomas, subarachnoid haemorrhage,
ischaemic lesions; mass effect; and the overall amount of tissue
damage were assessed with validated rating scales based on
previous work (see box).12-16 The individual ratings and
measurements were recorded on a rating form developed for
the purposes of this study (shown in appendix on bmj.com).
The primary outcome was total haemorrhage growth, defined
as the difference in the combined volume (mL) of all intracranial
haemorrhagic lesions (intra-parenchymal haematoma +
haemorrhagic contusion + subdural haematoma + epidural
haematoma) from the first to the second scan. Secondary
outcomes were (a) significant haemorrhage growth defined as
an increase by ≥25% of total haemorrhage in relation to its
initial volume, (b) new intracranial haemorrhage (apparent on
the second scan but not apparent on the first), (c) change in
subarachnoid haemorrhage grade, (d) mass effect, and (e) new
focal cerebral ischaemic lesions (apparent on the second scan
but not the first).
The clinical outcomes were death from any cause, dependency,
and the need for neurosurgical intervention. Clinical outcomes
were recorded at hospital discharge, at 28 days after
randomisation, or death, whichever occurred first. Dependency
was measured using the five point modified Oxford handicap
scale (mOHS).17 We dichotomised the scale into “dependent”
(fully dependent requiring attention day and night, or dependent
but not requiring constant attention) or “independent” (some
restriction in lifestyle but independent, minor symptoms, or no
symptoms). We also reported a “composite poor outcome”
defined as a patient who developed one or more of the following
during the follow-up period—significant haemorrhage growth,
new intracranial haemorrhage, new focal cerebral ischaemic
lesions, the need for neurosurgery, or death.
Adverse events that were serious, unexpected, and suspected to
be related to the study treatment were reported separately.
Sample size
Assuming an initial intracranial haemorrhage volume of 20 mL,
an average haemorrhage growth of 7 mL in the control group
and a correlation of 0.6 between initial and follow-up volumes,
we estimated that a trial with 300 patients would have 80%
power (α=0.05) to detect a 35% reduction in haemorrhage
growth. We pre-specified in the protocol that, as this study was
nested within the main CRASH-2 trial, even if the planned
sample size of 300 patients was not achieved, recruitment would
stop at the same time as the main CRASH-2 trial.
Randomisation
After eligibility had been confirmed and the locally approved
consent procedures had been completed, patients were randomly
assigned. Randomisation was balanced by centre, with an
allocation sequence based on a block size of eight. We used a
local pack system that selected the lowest numbered treatment
pack from a box containing eight numbered packs. Apart from
the pack number, the treatment packs were identical. The pack
number was recorded on the entry form, which was sent to the
international trial coordinating centre in London, UK. Once the
treatment pack number was recorded, the patient was included
in the trial whether or not the treatment pack was opened or the
allocated treatment started. All site investigators and trial
coordinating centre staff were masked to treatment allocation.
Blinding
Tranexamic acid and placebo ampoules were indistinguishable.
Tranexamic acid was manufactured by Pharmacia (Pfizer,
Sandwich, UK) and placebo by StMary’s Pharmaceutical Unit,
Cardiff, UK. The treatment packs were prepared by an
independent clinical trial supply company (Bilcare, Crickhowell,
UK). Correct blinding and coding of ampoules was assured by
independent random testing of each batch by high performance
liquid chromatography to confirm the contents.
Statistical methods
We assessed the intra-observer reliability of haemorrhage
measurements using the intra-class correlation coefficient. We
assessed the reliability of binary measurements with the κ
statistic. For continuous variables measuring the haemorrhage,
we used the average measurement of the two independent
readings in all analyses. For binary variables, we considered an
intracranial finding to be present only if it was reported as
present on both readings of a particular patient’s brain scan.
We used generalised linear models adjusted for baseline
variables. Covariates included in the adjustment were Glasgow
coma scale and age. For computed tomography outcomes, we
also adjusted for time from injury to first and second scan and
for initial haemorrhage volume. In our analysis of mass effect
we adjusted for initial mass effect. Adjusted effects are
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Methods used to measure brain lesions detected with computed tomography
Parenchymal haemorrhage and haemorrhagic contusion (defined as focal low attenuation with patchy and relatively
ill-defined haemorrhage)
Measurement—A representative slice at the centre of the haematoma was selected. The maximum linear length (A)
in cm was multiplied by the maximum width perpendicular to A (B) and the maximum depth (C) in cm. The depth (C)
was determined by multiplying the number of slices on which haematoma is visible by the slice interval thickness listed
on the CT scan. To obtain the volume in cm3 the final product (A.B.C) was divided by 2
Subdural haematomas
Measurement—A representative slice near the centre of the haematoma was selected. The linear distance in cm
between each corner of the subdural crescent was used to determine the length (A). The width (B) was measured as
the maximum thickness in cm of haematoma from the inner table of the skull perpendicular to the length. The depth
(C) was determined by multiplying the number of slices on which haematoma is visible by the slice interval thickness
listed on the CT scan. To obtain the volume in cm3 the final product (A.B.C) was divided by 2.
Epidural haematomas
Measurement—A representative slice near the centre of the haematoma was selected. The linear distance in cm
between each corner of the epidural lens shape was used to determine the length (A). The width (B) was measured
as the maximum thickness in cm of haematoma (B) from the inner table of the skull perpendicular to the length. The
depth (C) was determined by multiplying the number of slices on which haematoma is visible by the slice interval listed
on the CT scan. To obtain the volume in cm3, the final product (A.B.C) was divided by 2
Subarachnoid haemorrhage
Measurement—Blood within subarachnoid spaces between pia and arachnoid membranes. Haemorrhage thickness
was categorised as ≤5 mm or >5 mm. The thickness was rated within a representative sulcus
New focal ischaemic lesions
Measurement—Focal low attenuation in distribution indicating arterial ischaemic cause rather than traumatic contusional
injury rated according to validated scale for ischaemic stroke
Mass effect
Measurement—(1) sulcal effacement, (2) ventricular effacement, (3) uncal herniation, (4) cisterns compressed, (5)
cisterns absent, (6) Midline shift (in mm)
considered in the primary analysis, but both adjusted and
unadjusted effect measures are reported. We reported 95%
confidence intervals for all the effects estimated and P values
for the adjusted analyses.
Haemorrhage growth was analysed using multiple linear
regression (analysis of covariance), the main factor being the
treatment group. Outcomes are reported combined and separately
for patients who did or did not undergo neurosurgical evacuation
between the first and second computed tomography scan. Binary
outcomes were analysed using logistic regression. Subarachnoid
haemorrhage scale was compared in the two groups using a
non-parametric rank test (Kruskal-Wallis). All analyses were
undertaken on an intention to treat basis.
To evaluate the clinical relevance of the primary surrogate
outcome selected in this study, we also analysed the clinical
effect of haemorrhage growth. We conducted a logistic
regression analysis with dependency (as defined by themodified
Oxford handicap scale) as the outcome and haemorrhage growth
as the main exposure variable, with adjustment by the potential
confounders of initial haemorrhage volume, Glasgow coma
scale, age, time from injury to computed tomography, and
treatment.
We used the statistical software package Stata (version SE/11·0)
from StataCorp.
Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of the
report. The Writing Committee had full access to all data in the
study and had final responsibility for the decision to submit for
publication.
Results
We recruited 270 patients (133 allocated to tranexamic acid and
137 allocated to placebo) between August 2008 and January
2010 (figure).This nested study was stopped when the main
CRASH-2 trial’s pre-specified sample size of 20 000 was
achieved. All patients received the loading and maintenance
doses, except one patient allocated placebo who did not receive
the maintenance dose. All patients were followed up for clinical
outcomes. A total of 256 patients (95%) had the first computed
tomography scan. In 14 patients (six allocated to tranexamic
acid, eight controls allocated to placebo), the first scan was
unavailable for reading for technical reasons. Five patients died
before the second scan (three allocated to tranexamic acid, two
controls). Protocol deviations were as follows: nine (3%)
patients were randomised before the first computed tomography
(six allocated tranexamic acid, three controls); 31 (11%) had a
Glasgow coma scale of 15 at baseline (17 allocated tranexamic
acid, 14 controls); and in 51 (19%) the second computed
tomography was conducted outside the 24–48 hours window
(25 allocated tranexamic acid, 26 controls).
Baseline characteristics of the included patients and their first
brain scan findings are shown in tables 1 and 2. A total of 211
patients (82%) had some form of intracranial haemorrhage
(intraparenchymal haematoma, haemorrhagic contusion,
subdural haematoma, or epidural haematoma). Five patients
had a focal ischaemic lesion (two patients in the tranexamic
acid group, three controls). Forty patients (20 allocated
tranexamic acid, 20 controls) had neurosurgical evacuation on
the basis of findings from the first computed tomography scan.
Intra-observer reliability for reading computed tomographies
was high for all outcomes except new intracranial haemorrhages.
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The intra-class correlation coefficient for total haemorrhage
growth was 0.89. The κ scores for the categorical variables
significant haemorrhage growth, new intracranial haemorrhage,
any mass effect, and new focal cerebral ischaemic lesions were
0.82, 0.32, 0.81, and 0.89 respectively.
The mean initial intracranial haemorrhage volume was 16.8 mL
(SD 23.8) in the tranexamic acid group and 19.8 mL (28.3) in
the placebo group. Computed tomography outcomes were
available for 249 (99%) of the 251 patients who had a first brain
scan and were alive at 24 hours.
Primary outcome
The mean total haemorrhage growth was 5.9 mL (SD 26.8) and
8.1 mL (SD 29.2) in the tranexamic acid and placebo groups
respectively. The adjusted analysis showed a reduction in total
haemorrhage growth in the tranexamic acid group in comparison
with the controls of –3.8 mL (95% confidence interval –11.5
to 3.9, P=0.33) (table 3).
Other computed tomography outcomes
In the tranexamic acid and placebo groups respectively,
significant haemorrhage growth occurred in 44 (36%) and 56
(44%) patients, new haemorrhage areas occurred in 13 (11%)
and 20 (16%), signs of mass effect occurred in 58 (47%) and
76 (60%), and new focal cerebral ischaemic lesions occurred
in six (5%) and 12 (9%) (see table 4 for the unadjusted and
adjusted odds ratios).
The change in the subarachnoid haemorrhage scale was –0.11
for patients allocated tranexamic acid and –0.12 for control
patients (P=0.93).
Clinical outcomes
There were 14/133 (11%) deaths in the tranexamic acid group
and 24/137 (18%) in the placebo group (adjusted odds ratio 0.47
(95% confidence interval 0.21 to 1.04, P=0.06). Among the
survivors, a total of 26/119 (22%) patients in the tranexamic
acid group and 29/113 (26%) in the placebo group were
dependent at hospital discharge or 28 days (adjusted odds ratio
0.66 (0.32 to 1.36, P=0.26). Twenty (15%) of the 133 patients
in the tranexamic acid group and 21/137 (15%) in the placebo
group had neurosurgery other than those evacuations based on
first brain scan findings (adjusted odds ratio 0.98 (0.45 to 1.93)
P=0.95).
Composite outcomes
Sixty (45%) patients in the tranexamic acid group and 80 (58%)
in the placebo group had a “composite poor outcome” (adjusted
odds ratio 0.57 (0.33 to 0.98) P=0.04). No emergency unblinding
was needed, and there were no adverse events regarded as
serious, unexpected, or suspected to be related to the study
treatment.We also found that an increase in haemorrhage growth
of 10 mL was strongly associated with dependency at hospital
discharge (adjusted odds ratio 1.32 (1.08 to 1.62)).
Discussion
This is the first randomised controlled study to evaluate the
effect of tranexamic acid in patients with traumatic brain injury,
and we found that neither moderate benefits nor moderate
harmful effects can be excluded. However, despite the relatively
wide confidence intervals, our analyses suggest that tranexamic
acid administration might improve outcome after traumatic
brain injury and provide grounds for evaluating this hypothesis
in future research.
The Intracranial Bleeding Study was conducted among patients
with traumatic brain injury who also had significant extracranial
haemorrhage, and the effect of tranexamic acid might be
different in patients with isolated traumatic brain injury. It has
been suggested that, among patients with traumatic brain injury,
only those with hypotension activate the fibrinolytic response.18
It is possible that in our study population tranexamic acid
reduced extracranial bleeding, and therefore patients in the
tranexamic acid group were less hypotensive, and less
coagulopathic, and through this mechanism tranexamic acid
reduced the expansion of intracranial bleeding. However, only
7% of the included patients had a systolic blood pressure <90
mm Hg. Furthermore, we did not find evidence of treatment
interaction according to systolic blood pressure at admission (P
value for interaction for haemorrhage growth 0.38).
Additionally, a recent paper has challenged this basic hypothesis
by reporting that coagulopathy is also found in traumatic brain
injury patients without hypotension.19
The larger effect on haematoma growth observed in surgical
patients is consistent with the evidence of effectiveness of
antifibrinolytic agents in elective surgery, for which
antifibrinolytic agents have been shown to reduce blood loss.1
We found a reduction in new focal cerebral ischaemic lesions
in the patients allocated tranexamic acid. However, the overall
incidence of these lesions was low, and it is possible that the
observed difference between the groups may have arisen by
chance alone. Nevertheless, it is plausible that if tranexamic
acid reduces haemorrhage growth then this could reduce the
local pressure on arteries. Any reduction in intracranial pressure
might also reduce the risk of ischaemia. Given that tranexamic
acid has been shown to reduce mortality from bleeding, it is
also possible that patients allocated to tranexamic acid may have
had a more stable circulation and that this may have accounted
for the observed reduction in ischaemic lesions. Our findings
differ from those reported in a systematic review of randomised
controlled trials of tranexamic acid in patients with aneurysmal
subarachnoid haemorrhage, which found that tranexamic acid
reduced the rate of re-bleeding but increased cerebral
ischaemia.20 However, the doses of tranexamic acid used in
these trials were larger and more prolonged than in our study.
Furthermore, the risk and mechanism of cerebral ischaemia is
different in the two conditions.
Regarding the clinical outcomes, although the results were not
statistically significant, we found a trend towards a reduction
in mortality, without any evidence of increase in dependency
among survivors.
When we assessed the effect of tranexamic acid on a composite
outcome that considered poor computed tomography and clinical
outcomes we found a statistically significant reduction.
Importantly, this composite outcomewas pre-specified, and the
effect on all the outcomes included in the composite outcome
showed the same direction towards benefit.21
Strengths and limitations of study
Our study has several strengths. It was a prospective study which
collected detailed computed tomographic data, with clear
inclusion criteria, pre-specified outcomes, and statistical analysis
plan. The randomisation methods ensured that participating
clinicians did not have foreknowledge of treatment allocation,
baseline clinical factors were well balanced, there was high
follow-up, and all analyses were performed on an intention to
treat basis. Although there were baseline differences between
patients allocated tranexamic acid and those allocated placebo
in some scan findings, the adjusted analyses should have
Reprints: http://journals.bmj.com/cgi/reprintform Subscribe: http://resources.bmj.com/bmj/subscribers/how-to-subscribe
BMJ 2011;343:d3795 doi: 10.1136/bmj.d3795 Page 4 of 11
RESEARCH
accounted for any imbalance. We attempted to minimise
measurement error through the use of central computed
tomogram reading by an experienced neuroradiologist, following
a pre-specified validated protocol of qualitative and quantitative
methods to assess brain damage. The protocol used previously
validated methods, and those that had not been previously
validated were further tested in the present study.We found that
intra-rater reliability was high for most imaging measurements.
Among the limitations, our study included only a relatively
small sample of the CRASH-2 participants with traumatic brain
injury, and a larger sample size could have provided more
precise results. The nature of a large pragmatic trial such as the
CRASH-2 trial constrained our ability to collect computed
tomograms for all the patients with traumatic brain injury
included in the CRASH-2 trial. Nevertheless, the relatively
small sample size does not affect the internal validity of this
study, and, although imprecise, the results should be unbiased.
Implications of results
The CRASH-2 trial has shown reliably that early administration
of tranexamic acid in trauma patients with, or at risk of,
significant bleeding reduces the risk of all cause mortality. As
a consequence of this trial, tranexamic acid has been
incorporated into trauma treatment protocols worldwide. Many
patients with traumatic haemorrhage also have traumatic brain
injury, and concerns about the risk of cerebral ischaemia may
affect decisions whether to give tranexamic acid to these
patients.22 The results presented here are the only available
evidence to inform doctors about the effect of tranexamic acid
on brain ischaemic lesions in patients with traumatic
haemorrhage and traumatic brain injury, and, although
imprecise, the results should give some reassurance about the
safety of tranexamic acid in such patients.
Our results also have important research implications. In theory,
if tranexamic acid reduces intracranial haemorrhage after
traumatic brain injury without increasing the risk of ischaemic
lesions, it could substantially improve patient outcomes. Until
now, however, no trial has evaluated the effect of tranexamic
acid in patients with traumatic brain injury. Our results suggest
it is probable that, in such patients, the benefits of tranexamic
acid administration would outweigh the risks. If such an
inexpensive and widely practicable treatment were found to
improve patient outcomes after traumatic intracranial
haemorrhage this would have major implications for clinical
care. The CRASH-3 trial (http://crash3.lshtm.ac.uk/) will
determine reliably the effectiveness of the early administration
of a short course of tranexamic acid in patients with traumatic
brain injury.
The database programming was carried out by Tony Brady of Sealed
Envelope.
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Tables
Table 1| Baseline clinical characteristics of patients with, or at risk of, serious extracranial bleeding and traumatic brain injury who were
allocated to tranexamic acid or placebo. Values are numbers (percentages) of patients unless stated otherwise
Placebo (n=137)Tranexamic acid (n=133)Characteristics
Sex:
117 (85)111 (84)Male
20 (15)22 (16)Female
37 (14)36 (14)Mean (SD) age (years)
Glasgow coma scale:
58 (42)63 (47)Mild (15–13)
34 (25)25 (19)Moderate (12–9)
45(33)45 (34)Severe (8–3)
Systolic blood pressure (mm Hg):
10 (7)9 (7)<90
69 (50)63 (47)90–119
58 (43)61 (46)≥120
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Table 2| Results from baseline computed tomography of patients with, or at risk of, serious extracranial bleeding and traumatic brain injury
who were allocated to tranexamic acid or placebo. Values are numbers (percentages) of patients
Placebo (n=129)Tranexamic acid (n=127)Computed tomographic characteristics
3 (2)4 (3)Normal
22 (17)26 (20)Mild focal injury
41 (32)39 (31)Medium focal injury
19 (15)23 (18)Mild or moderate diffuse injury
23 (18)17 (13)Massive focal injury (with or without diffuse injury)
21 (16)18 (14)Massive diffuse injury (with or without focal injury)
Types of haemorrhage*
15 (12)9 (7)Intraparenchymal haematoma
66 (51)61 (48)Haemorrhagic contusion
45 (35)38 (30)Subdural haematoma
28 (22)38 (30)Epidural haematoma
105 (81)106 (83)Any intracranial haemorrhage†
79 (61)55 (43)Subarachnoid haemorrhage
Mass effect findings*
73(57)59 (46)Sulcal effacement
43 (33)37 (29)Ventricular effacement
14(11)14(11)Uncal herniation
13 (10)11(9)Cisterns compressed
3 (2)1 (1)Cisterns absent
* Haemorrhage and mass effect categories are not mutually exclusive, so totals can be >100%.
†Includes intraparenchymal, haemorrhagic contusion, subdural, or epidural haemorrhage.
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Table 3| Effect of tranexamic acid on total haemorrhage growth among patients with, or at risk of, serious extracranial bleeding and traumatic
brain injury who were allocated tranexamic acid or placebo. Values are difference (95% confidence interval) between patients allocated
tranexamic acid and controls unless stated otherwise
P value†
Difference in haemorrhage growth (ml)
Adjusted values*Unadjusted values
0.33–3.79 (–11.5 to 3.9)–2.1 (–9.8 to 5.6)All patients (n=206):
0.32–15.5 (–46.5 to 15.5)–6.3 (–35.0 to 22.4)Neurosurgery (n=46)
0.40–2.11 (–7.1 to 2.9)–1.6 (–7.3 to 4.0)No neurosurgery (n=160)
*Adjusted by Glasgow coma scale, age, time from injury to first computed tomography, time from injury to second computed tomography, and initial haemorrhage
volume.
†For the adjusted analyses.
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Table 4| Effect of tranexamic acid on binary outcomes from computed tomography among patients with, or at risk of, serious extracranial
bleeding and traumatic brain injury who were allocated tranexamic acid or placebo
P value‡
Odds ratio (95% CI)No (%) of patients
Adjusted*UnadjustedPlacebo (n=126)
Tranexamic acid
(n=123)
0.130.67 (0.40 to 1.13)0.70 (0.42 to 1.16)56 (44)44 (36)Substantial
haemorrhage growth
0.220.62 (0.28 to 1.35)0.63 (0.30 to 1.33)20 (16)13 (11)New haemorrhage
0.120.53 (0.23 to 1.21)0.59 (0.35 to 0.97)76 (60)58 (47)Any mass effect†
0.200.51 (0.18 to 1.44)0.49 (0.18 to 1.35)12 (9)6 (5)New focal ischaemic
regions
*Adjusted by Glasgow coma scale, age, time from injury to first computed tomography, time from injury to second computed tomography, and initial haemorrhage
volume.
†Adjusted by Glasgow coma scale, age, time from injury to first computed tomography, time from injury to second computed tomography, initial haemorrhage
volume, and initial mass effect.
‡For the adjusted analyses.
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Figure
Fig 1 Summary of patient flow through trial
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